These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 32887711

  • 1. Medicaid Expansion and Utilization of Antihyperglycemic Therapies.
    Sumarsono A, Buckley LF, Machado SR, Wadhera RK, Warraich HJ, Desai RJ, Everett BM, McGuire DK, Fonarow GC, Butler J, Pandey A, Vaduganathan M.
    Diabetes Care; 2020 Nov; 43(11):2684-2690. PubMed ID: 32887711
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2035792. PubMed ID: 33523188
    [Abstract] [Full Text] [Related]

  • 3. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, Henderson R, Parekh N.
    J Manag Care Spec Pharm; 2021 Apr 01; 27(4):435-443. PubMed ID: 33769857
    [Abstract] [Full Text] [Related]

  • 4. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
    Hamid A, Vaduganathan M, Oshunbade AA, Ayyalasomayajula KK, Kalogeropoulos AP, Lien LF, Shafi T, Hall ME, Butler J.
    J Cardiovasc Pharmacol; 2020 Sep 01; 76(3):313-320. PubMed ID: 32569016
    [Abstract] [Full Text] [Related]

  • 5. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014.
    Mahendraratnam N, Dusetzina SB, Farley JF.
    J Manag Care Spec Pharm; 2017 Mar 01; 23(3):355-363. PubMed ID: 28230452
    [Abstract] [Full Text] [Related]

  • 6. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F, Kazem N, Schweitzer R, Hammer A, Jakse F, Koller L, Hengstenberg C, Sulzgruber P, Niessner A.
    Cardiovasc Drugs Ther; 2021 Dec 01; 35(6):1161-1170. PubMed ID: 33666822
    [Abstract] [Full Text] [Related]

  • 7. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R, Jha K, Dardari Z, Heyward J, Blumenthal RS, Eckel RH, Alexander GC, Blaha MJ.
    J Am Heart Assoc; 2022 May 03; 11(9):e023811. PubMed ID: 35475341
    [Abstract] [Full Text] [Related]

  • 8. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
    Tang EHM, Wong CKH, Lau KTK, Fei Y, Cheung BMY.
    Diabetes Res Clin Pract; 2021 Oct 03; 180():109071. PubMed ID: 34592391
    [Abstract] [Full Text] [Related]

  • 9. Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction.
    Wadhera RK, Bhatt DL, Wang TY, Lu D, Lucas J, Figueroa JF, Garratt KN, Yeh RW, Joynt Maddox KE.
    JAMA Cardiol; 2019 Feb 01; 4(2):120-127. PubMed ID: 30649146
    [Abstract] [Full Text] [Related]

  • 10. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
    Li C, Guo S, Huo J, Gao Y, Yan Y, Zhao Z.
    Front Endocrinol (Lausanne); 2022 Feb 01; 13():987081. PubMed ID: 36277697
    [Abstract] [Full Text] [Related]

  • 11. Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020.
    Mittman BG, Le P, Payne JY, Ayers G, Rothberg MB.
    Curr Med Res Opin; 2024 Mar 01; 40(3):377-383. PubMed ID: 38193509
    [Abstract] [Full Text] [Related]

  • 12. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
    Deo SV, McAllister DA, Al-Kindi S, Elgudin Y, Chu D, Pell J, Sattar N.
    Diabetes Care; 2022 Dec 01; 45(12):3054-3057. PubMed ID: 36256925
    [Abstract] [Full Text] [Related]

  • 13. Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study.
    DeRemer CE, Vouri SM, Guo J, Donahoo WT, Winterstein AG, Shao H.
    J Diabetes Complications; 2021 Sep 01; 35(9):107972. PubMed ID: 34247911
    [Abstract] [Full Text] [Related]

  • 14. County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries.
    Hanna J, Nargesi AA, Essien UR, Sangha V, Lin Z, Krumholz HM, Khera R.
    Am J Prev Cardiol; 2022 Sep 01; 11():100370. PubMed ID: 35968531
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Tsapas A, Bekiari E.
    Diabetes Obes Metab; 2020 Oct 01; 22(10):1857-1868. PubMed ID: 32476254
    [Abstract] [Full Text] [Related]

  • 16. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
    Essien UR, Singh B, Swabe G, Johnson AE, Eberly LA, Wadhera RK, Breathett K, Vaduganathan M, Magnani JW.
    JAMA Netw Open; 2023 Jun 01; 6(6):e2316290. PubMed ID: 37261826
    [Abstract] [Full Text] [Related]

  • 17. Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018.
    Sumarsono A, Lalani H, Segar MW, Rao S, Vaduganathan M, Wadhera RK, Das SR, Navar AM, Fonarow GC, Pandey A.
    Circ Cardiovasc Qual Outcomes; 2021 Jan 01; 14(1):e007492. PubMed ID: 33161766
    [Abstract] [Full Text] [Related]

  • 18. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E.
    Diabetes Care; 2020 Apr 01; 43(4):921-924. PubMed ID: 32041899
    [Abstract] [Full Text] [Related]

  • 19. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases.
    Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, Al-Aly Z.
    Diabetes Care; 2020 Nov 01; 43(11):2859-2869. PubMed ID: 32938746
    [Abstract] [Full Text] [Related]

  • 20. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.